Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Equities research analysts at Stifel Canada upped their FY2025 earnings per share estimates for Bradmer Pharmaceuticals in a report released on Tuesday, November 12th. Stifel Canada analyst B. Papanastasiou now expects that the company will post earnings of $2.28 per share for the year, up from their prior estimate of $1.83.
Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported C($0.18) EPS for the quarter, beating the consensus estimate of C($0.52) by C$0.34.
View Our Latest Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- Trading Halts Explained
- How Whitestone REIT Is Transforming Sun Belt Retail Growth
- 5 discounted opportunities for dividend growth investors
- Top-Performing Non-Leveraged ETFs This Year
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
